Actively Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Led by Sangamo Therapeutics · Updated on 2026-04-30
27
Participants Needed
11
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
CONDITIONS
Official Title
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnostic confirmation of Small Fiber Neuropathy (SFN) using ACTTION criteria
- Pain that has not improved after at least 6 months of treatment with 2 of 3 first-line therapies
- Negative blood test for anti-AAV9 antibodies before enrollment
You will not qualify if you...
- Using opioid pain medicines for less than 3 months, or not on a stable opioid dose
- History of alcohol, opioid, or illicit drug abuse within 2 years before screening
- Positive drug test without prescription or approval
- Use of cannabinoids is not allowed
- Having Fabry's disease, erythromelalgia, alcohol or drug-related peripheral neuropathy, or diagnosed channelopathies
- Medical reasons preventing lumbar puncture or anesthesia
- Active viral or bacterial infections
- Severe infection within 12 weeks before screening
- Significant liver disease or abnormal liver function tests
- Use of liver-toxic medications or supplements during the study
- History of cancer within 5 years except certain stable skin, prostate, or breast cancers
- Previous gene or cellular therapy treatment
- History of bone marrow, stem cell, or organ transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
HonorHealth
Scottsdale, Arizona, United States, 85260
Actively Recruiting
2
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Actively Recruiting
3
The University of California, San Diego
La Jolla, California, United States, 92093
Not Yet Recruiting
4
Johns Hopkins University
Baltimore, Maryland, United States, 21218
Not Yet Recruiting
5
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
6
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03766
Not Yet Recruiting
7
Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
New York, New York, United States, 10027
Actively Recruiting
8
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States, 27514
Not Yet Recruiting
9
Vanderbilt University
Nashville, Tennessee, United States, 37235
Not Yet Recruiting
10
University of Utah
Salt Lake City, Utah, United States, 84112
Not Yet Recruiting
11
Virginia Commonwealth University
Richmond, Virginia, United States, 23284
Actively Recruiting
Research Team
P
Patient Advocacy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here